Answers are grounded in this paper and cite their sources.
Introduction Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. Accumulation of glycosaminoglycans leads to progressive disease affecting multiple organ systems. In the neuronopathic form, involvement of the central nervous system (CNS) is associated with cognitive decline and a poorer prognosis. Conventional intravenous enzyme replacement therapy has little effect on the CNS because of limited blood-brain barrier penetration. In March 2026, the U.S. Food and Drug Administration granted accelerated approval to tividenofusp alfa, the first approved treatment specifically intended to address the neurological complications of Hunter syndrome. The aim of this review is to summarize the available evidence on the effectiveness of tividenofusp alfa in the treatment of Neuronopathic MPS II. Materials and methods A focused narrative search of PubMed, ClinicalTrials.gov, and U.S. Food and Drug Administration sources was conducted through 16 August 2026. Search terms included "Hunter syndrome," "mucopolysaccharidosis type II," "tividenofusp alfa," "DNL310," "idursulfase," and "brain-penetrant enzyme replacement therapy." We reviewed reference lists of key articles for background sources. Results Tividenofusp alfa crosses the blood-brain barrier through transferrin receptor-mediated transcytosis and is then taken up by cells, allowing iduronate-2-sulfatase to reach the lysosome. In the phase 1/2 study, 47 male participants received weekly infusions for 24 weeks followed by 80-week safety extension. At week 24, mean cerebrospinal fluid heparan sulfate levels fell by 91%, and 93% of evaluable participants had levels below the upper limit of normal. Treatment-emergent adverse events were common, most often infusion-related reactions in more than 40% of the participants. Phase 2/3 and extension studies are evaluating the longer-term clinical effects and safety of treatment. Conclusion Tividenofusp alfa provides a new treatment option for Neuronopathic MPS II. However, its accelerated approval was based on a surrogate biomarker, and its long-term effects on neurodevelopment and other clinical outcomes remain uncertain.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: